Inhaled interferon falls short for COVID-19 discharge, recovery but hints of other benefits: SPRINTER

SAN FRANCISCO — Treatment with inhaled interferon beta failed to improve discharge and recovery in patients hospitalized with moderate COVID-19, according to results of the phase 3 SPRINTER trial.
“While the study did not meet its primary efficacy endpoints looking at hospital discharge and recovery, potentially due to changes in standard of care, there were trends in favor of SNG001 in prevention of progression to severe disease or death,” Phillip Monk, PhD, chief scientific officer of Synairgen, said during a presentation at the American Thoracic Society International

SAN FRANCISCO — Treatment with inhaled interferon beta failed to improve discharge and recovery in patients hospitalized with moderate COVID-19, according to results of the phase 3 SPRINTER trial.
“While the study did not meet its primary efficacy endpoints looking at hospital discharge and recovery, potentially due to changes in standard of care, there were trends in favor of SNG001 in prevention of progression to severe disease or death,” Phillip Monk, PhD, chief scientific officer of Synairgen, said during a presentation at the American Thoracic Society International